The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
Open accessAbstract
Abstract Introduction [ 177 Lu]Lu-PSMA-617 (Lu-PSMA) radioligand therapy is an emerging treatment option for patients with end-stage prostate cancer. However, response to Lu-PSMA therapy is only achieved in approximately half of patients. It is clinically important to identify patients at risk of poor outcome. Therefore, the aim of this study was to evaluate pretherapeutic PSMA PET derived total tumor volume and related metrics as prognosticators of overall survival in patients receiving Lu-PSMA therapy. Methods A total number of 110 patients form the Departments of Nuclear Medicine Münster and Essen were included in this retrospective analysis. Baseline PSMA PET-CT was available for all patients. Employing a previously published approach, all tumor lesions were semi-automatically delineated in PSMA PET-CT acquisitions. Total lesion number, total tumor volume (PSMA-TV), total lesion uptake (PSMA-TLU = PSMA-TV * SUV mean ), and total lesion quotient (PSMA-TLQ = PSMA-TV / SUV mean) were quantified for each patient. Log2 transformation was used for regressions. Results Lesion number, PSMA-TV, and PSMA-TLQ were prognosticators of overall survival (HR = 1.255, p = 0.009; HR = 1.299, p = 0.005; HR = 1.326, p = 0.002). In a stepwise backward Cox regression including lesion number, PSMA-TV, PSA, LDH, and PSMA-TLQ, only the latter two remained independent and statistically significant negative prognosticators of overall survival (HR = 1.632, p = 0.011; HR = 1.239, p = 0.024). PSMA-TLQ and LDH were significant negative prognosticators in multivariate Cox regression in contrast to PSA value. Conclusion PSMA-TV was a statistically significant negative prognosticator of overall survival in patients receiving Lu-PSMA therapy. PSMA-TLQ was an independent and superior prognosticator of overall survival compared with PSMA-TV.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Initial results also show a prognostic value of PSMA-PET tumor volume in prostate cancer prior to radioligand therapy with [177Lu]Lu-PSMA-617 [204].”
From Influences on PET Quantification and Interpretation (2022) · cites this paper as [204]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., Wong, Y., Hahn, N. M., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,958
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C. S., Basch, E., Fizazi, K. S., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,707
Hofman, M. S., Violet, J. A., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T. J., Iravani, A., Kong, G., Kumar, A. S. R., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,184
Kyriakopoulos, C. E., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Hahn, N. M., Shevrin, D. H., Dreicer, R., Hussain, M., Eisenberger, M. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3657 · Cited by 1,108
Rahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schäfers, M. A., Essler, M., Baum, R. P., Kulkarni, H., Schmidt, M. C., Drzezga, A. E., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183194 · Cited by 861
Self-citationAggarwal, R., Huang, J., Alumkal, J. J., Zhang, L., Feng, F. Y., Thomas, G. V., Weinstein, A. S., Friedl, V., Zhang, C., Witte, O. N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6880 · Cited by 810
On the exact distribution of maximally selected rank statistics
Hothorn, T., & Lausen, B. (2003) · Computational Statistics & Data Analysis · doi:10.1016/s0167-9473(02)00225-6 · Cited by 694
Sartor, O., & de Bono, J. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1701695 · Cited by 546
Violet, J., Jackson, P., Ferdinandus, J., Sandhu, S., Akhurst, T., Iravani, A., Kong, G., Kumar, A. R., Thang, S. P., Eu, P., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.219352 · Cited by 504 · cited 2×
“In line with the concept of theranostics, high SUVmean is associated with higher tumor doses of Lu-PSMA therapy and should therefore be linked to a favorable outcome [25].”
BackgroundHalabi, S., Kelly, W. K., Ma, H., Zhou, H., Solomon, N. C., Fizazi, K., Tangen, C. M., Rosenthal, M., Petrylak, D. P., Hussain, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.7270 · Cited by 461
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)
Kratochwil, C., Fendler, W. P., Eiber, M., Baum, R. P., Bozkurt, M. F., Czernin, J. G., Bolton, R. C. D., Ezziddin, S., Forrer, F., Hicks, R. J., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04485-3 · Cited by 387
Self-citationUprimny, C., Kroiss, A. S., Decristoforo, C., Fritz, J., von Guggenberg, E., Kendler, D., Scarpa, L., di Santo, G., Roig, L. G., Maffey-Steffan, J., et al. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3631-6 · Cited by 342
Ahmadzadehfar, H., Rahbar, K., Kürpig, S., Bögemann, M., Claesener, M., Eppard, E., Gärtner, F., Rogenhofer, S., Schäfers, M. A., & Essler, M. (2015) · EJNMMI Research · doi:10.1186/s13550-015-0114-2 · Cited by 293
Self-citationNeuroendocrine differentiation of prostate cancer leads to PSMA suppression
Bakht, M. K., Derecichei, I., Li, Y., Ferraiuolo, R., Dunning, M., Oh, S. W., Hussein, A. A., Youn, H., Stringer, K. F., Jeong, C. W., et al. (2018) · Endocrine Related Cancer · doi:10.1530/erc-18-0226 · Cited by 194
Rahbar, K., Bode, A., Weckesser, M., Avramović, N., Claesener, M., Stegger, L., & Bögemann, M. (2016) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000001240 · Cited by 186
Self-citationHofman, M. S., Emmett, L., Violet, J. A., Zhang, A. Y., Lawrence, N. J., Stockler, M. R., Francis, R. J., Iravani, A., Williams, S., Azad, A., et al. (2019) · British Journal of Urology · doi:10.1111/bju.14876 · Cited by 166
Ferdinandus, J., Violet, J. A., Sandhu, S. K., Hicks, R. J., Kumar, A. S. R., Iravani, A., Kong, G., Akhurst, T. J., Thang, S. P., Murphy, D. G., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04723-z · Cited by 165
Seifert, R., Seitzer, K. E., Herrmann, K., Kessel, K., Schäfers, M. A., Kleesiek, J., Weckesser, M., Boegemann, M., & Rahbar, K. (2020) · Theranostics · doi:10.7150/thno.47251 · Cited by 139
Self-citationDenmeade, S. R., Sokoll, L. J., Dalrymple, S. L., Rosen, D. M., Gady, A. M., Bruzek, D. J., Ricklis, R. M., & Isaacs, J. T. (2003) · The Prostate · doi:10.1002/pros.10199 · Cited by 136
Seifert, R., Herrmann, K., Kleesiek, J., Schäfers, M. A., Shah, V. P., Xu, Z., Chabin, G., Grbić, S., Spottiswoode, B. S., & Rahbar, K. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.242057 · Cited by 132
Self-citationGafita, A., Bieth, M., Krönke, M., Tetteh, G., Navarro, F., Wang, H., Günther, E., Menze, B. H., Weber, W., & Eiber, M. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.224055 · Cited by 127
Armstrong, A. J., Anand, A., Edenbrandt, L., Bondesson, E., Bjartell, A. S., Widmark, A., Sternberg, C. N., Пили, Р., Tuvesson, H., Nordle, Ö., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.1093 · Cited by 103
Rahbar, K., Bodei, L., & Morris, M. J. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.234054 · Cited by 70
Self-citationGafita, A., Fendler, W. P., Wang, H., Sandhu, S. K., Weber, M., Esfandiari, R., Calais, J., Rauscher, I., Rathke, H. G., Tauber, R., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.05.004 · Cited by 62
Self-citationRadioligand therapy using [177Lu]Lu-PSMA-617 in mCRPC: a pre-VISION single-center analysis
Seifert, R., Kessel, K., Schlack, K., Weckesser, M., Bögemann, M., & Rahbar, K. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04703-3 · Cited by 46
Self-citationHofman, M. S., Emmett, L., Violet, J. A., Lawrence, N. J., Williams, S., Stockler, M. R., Francis, R. J., Iravani, A., Zhang, A. Y., Martin, A. J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.tps332 · Cited by 6
Cited by
Sorted by citations
Seifert, R., Emmett, L., Rowe, S. P., Herrmann, K., Hadaschik, B. A., Calais, J., Giesel, F. L., Reiter, R. E., Maurer, T., Heck, M. M., et al. (2023) · European Urology · doi:10.1016/j.eururo.2023.02.002 · Cited by 333
Self-citationSayar, E., Patel, R. A., Coleman, I. M., Roudier, M. P., Zhang, A., Mustafi, P., Low, J., Hanratty, B. P., Ang, L. S., Bhatia, V., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.162907 · Cited by 95
Johnsson, K., Brynolfsson, J., Sahlstedt, H., Nickols, N. G., Rettig, M. B., Probst, S., Morris, M. J., Bjartell, A. S., Eiber, M., & Anand, A. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05497-8 · Cited by 64
Rosar, F., Krause, J., Bartholomä, M. D., Maus, S., Stemler, T., Hierlmeier, I., Linxweiler, J., Ezziddin, S., & Khreish, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050722 · Cited by 61
Pathmanandavel, S., Crumbaker, M., Yam, A. O. W., Nguyen, A., Rofe, C., Hovey, E. J., Gedye, C. A., Kwan, E. M., Hauser, C., Azad, A., et al. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262552 · Cited by 60
Metadata
- Authors
- Seifert, R., Kessel, K., Schlack, K., Weber, M., Herrmann, K., Spanke, M., Fendler, W. P., Hadaschik, B., Kleesiek, J., Schäfers, M., Weckesser, M., Boegemann, M., & Rahbar, K.
- Affiliations
- University Hospital Münster (DE)
- Essen University Hospital (DE)
- German Cancer Research Center (DE)
- Corresponding author
- Rahbar, Kambiz
- ORCID
- Venue
- European Journal of Nuclear Medicine and Molecular Imaging
- Published
- 2020-09-24
- Volume
- 48
- Issue
- 4
- Pages
- 1200-1210
- ISSN
- 1619-7070 (ISSN-L)
- 1619-7089
- PMC
- PMC8041668
- OpenAlex
- W3088497176
- Cited by
- 160
- References
- 26
- Citations by year
- 2026: 31 · 2025: 31 · 2024: 25 · 2023: 26 · 2022: 20 · 2021: 24 · 2020: 2
- FWCI
- 8.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Informationszentrum Lebenswissenschaften (ZB MED) (submittedVersion, cc-by)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Westfälische Wilhelms-Universität Münster
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- 177Lu-PSMA-617, radioligand therapy, advanced prostate cancer, PSMA PET/CT, total tumor volume, prognostic factors, overall survival, PSMA-617, PSMA-11, tumor volume measurement
- MeSH terms
- Positron Emission Tomography Computed Tomography, Dipeptides, Heterocyclic Compounds, 1-Ring, Humans, Male, Retrospective Studies, Treatment Outcome, Prostate-Specific Antigen, Tumor Burden, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
